



10 Recd

04 OCT 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D. C. 20231.

Date: October 1, 2002

Brian M. Berliner

PATENT
216019-50 (formerly 98,634-F)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Carson et. al

Serial No.: 09/831,690

International Filing Date: November 12,
1999

Priority Date: November 12, 1998

Title: Gene Expression Modulated by
Activation of Microglia or Macrophages

Art Unit:

Examiner:

MISSING PARTS TRANSMITTAL LETTER

BOX MISSING PARTS
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the copy of the Notice of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office dated November 26, 2001 and a CRF Problem Report (Processed August 6, 2002), enclosed please find the following:

1. Copy of the Notice of Missing Requirements
2. Copy of the CRF Report

Serial No. 09/831,690
October 1, 2002
Page 2

3. Re-submission of the Electronic and written copy of the sequence listing in PatentIn 3.1 format.

The sequence listing recorded and submitted herewith in computer readable form is identical to the written sequence listing submitted herewith, is substantially identical to the written copy of the sequence listing submitted in the international stage of this application, and contains no new matter.

The Commissioner of Patents is authorized to charge any amount due, or credit any overpayment, to Deposit Account No. 50-0639. A duplicate copy of this paper is enclosed.

Respectfully submitted,



Brian M. Berliner
Attorney for Applicants
Registration No. 34,549

Date: October 1, 2002

O'MELVENY & MYERS LLP
400 South Hope Street
Los Angeles, CA 90071-2899
Telephone: (213) 430-6000

10 Recd ~~copy~~ 4 OCT 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 09/831,690	FIRST NAMED APPLICANT Monica J Carson	ATTY. DOCKET NO. 98,634-F
---	--	------------------------------

INTERNATIONAL APPLICATION NO.

PCT/US99/26824

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

11/12/1999

11/12/1998

Roger P Zimmerman
 McDonnell Boehnen Hulbert & Berghoff
 300 South Wacker Drive
 Suite 3200
 Chicago, IL 60606



CONFIRMATION NO. 9615

371 FORMALITIES LETTER



OC000000007116110

Date Mailed: 11/26/2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Request for Immediate Examination
- Small Entity Statement

DOCKETED

SEP 09 2002

DUE DATE: _____

BY: _____

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e),